Aspira Women's Health appoints Torsten Hombeck as CFO, effective June 15, 2023

Aspira Women's Health Inc.

Torsten Hombeck, Ph.D., named CFO; previously CFO of Akari Therapeutics.
Annual base salary of $325,000 with bonus eligibility up to 50% of base.
Initial stock option grant of 13,333 shares, vesting 33.3% annually over 3 years.
Severance: 6 months base salary and COBRA if terminated without cause or resigns for good reason.
Subject to 12-month non-compete and non-solicitation covenants.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Torsten Hombeck

Chief Financial Officer

AWHL · Aspira Women's Health Inc.

Effective: 2023-06-15
Filed: May 16, 2023, 7:59 PM ET

appointed Tortsten Hombeck, Ph.D. as the Company’s Chief Financial Officer, effective as of June 15, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Torsten Hombeck was appointed as Chief Financial Officer at Aspira Women's Health Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

appointed Tortsten Hombeck, Ph.D. as the Company’s Chief Financial Officer, effective as of June 15, 2023

View on SEC.gov

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-23-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.